Outcome and long-term treatment protocol for topical tacrolimus in oral lichen planus.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
30
11
2021
accepted:
12
07
2022
pubmed:
24
7
2022
medline:
16
11
2022
entrez:
23
7
2022
Statut:
ppublish
Résumé
Topical tacrolimus has been shown to be beneficial in the treatment of oral lichen planus (OLP). However, long-term effects and its optimal application protocol with gradual reduction have not been studied. Accordingly, we analysed the clinical response of OLP to tacrolimus in our daily clinical practice with a focus on the optimal long-term therapeutic scheme. Retrospective analysis of all consecutive patients diagnosed with OLP and treated with topical tacrolimus (0.03% oral rinse) in a clinical setting between 2015 and 2020. The objective clinical response was measured by a 4-point scale (complete remission, major remission, partial remission and no response), and subjective impairment by a 3-point scale (severe, moderate and none). Fifty-seven patients (74% women; median age: 66 years) were included. Fifty-six (98%) patients had prior treatment with topical steroids. After introduction of tacrolimus, objective remission (major or complete) was reached by 28%, 62%, 87% and 97% of patients after 3, 6, 12 and 24 months respectively. Subjective remission was reported by 16%, 48%, 69% and 83% after 3, 6, 12 and 24 months of treatment respectively. The treatment frequency could be gradually reduced from initially twice daily to once daily or less in 28%, 61%, 78% and 87% after 3, 6, 12 and 24 months respectively; 41% of patients completely suspended the treatment at one point, but 67% of them experienced a relapse after a median time of 3.3 months. Four patients (7%) developed a squamous cell carcinoma (SCC) during the observation period. Otherwise, there were only few and minor side-effects. Topical tacrolimus can be an effective second-line therapy for OLP refractory to potent topical corticosteroids. The therapy frequency can often be reduced during the maintenance period. Both signs of clinical activity and subjective impairment should guide therapy. Regular follow-up is necessary to recognize possible SCC.
Sections du résumé
BACKGROUND AND OBJECTIVE
OBJECTIVE
Topical tacrolimus has been shown to be beneficial in the treatment of oral lichen planus (OLP). However, long-term effects and its optimal application protocol with gradual reduction have not been studied. Accordingly, we analysed the clinical response of OLP to tacrolimus in our daily clinical practice with a focus on the optimal long-term therapeutic scheme.
METHODS
METHODS
Retrospective analysis of all consecutive patients diagnosed with OLP and treated with topical tacrolimus (0.03% oral rinse) in a clinical setting between 2015 and 2020. The objective clinical response was measured by a 4-point scale (complete remission, major remission, partial remission and no response), and subjective impairment by a 3-point scale (severe, moderate and none).
RESULTS
RESULTS
Fifty-seven patients (74% women; median age: 66 years) were included. Fifty-six (98%) patients had prior treatment with topical steroids. After introduction of tacrolimus, objective remission (major or complete) was reached by 28%, 62%, 87% and 97% of patients after 3, 6, 12 and 24 months respectively. Subjective remission was reported by 16%, 48%, 69% and 83% after 3, 6, 12 and 24 months of treatment respectively. The treatment frequency could be gradually reduced from initially twice daily to once daily or less in 28%, 61%, 78% and 87% after 3, 6, 12 and 24 months respectively; 41% of patients completely suspended the treatment at one point, but 67% of them experienced a relapse after a median time of 3.3 months. Four patients (7%) developed a squamous cell carcinoma (SCC) during the observation period. Otherwise, there were only few and minor side-effects.
CONCLUSION
CONCLUSIONS
Topical tacrolimus can be an effective second-line therapy for OLP refractory to potent topical corticosteroids. The therapy frequency can often be reduced during the maintenance period. Both signs of clinical activity and subjective impairment should guide therapy. Regular follow-up is necessary to recognize possible SCC.
Identifiants
pubmed: 35870137
doi: 10.1111/jdv.18457
pmc: PMC9804806
doi:
Substances chimiques
Tacrolimus
WM0HAQ4WNM
Immunosuppressive Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2459-2465Informations de copyright
© 2022 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
Références
Med Clin (Barc). 2017 Oct 23;149(8):351-362
pubmed: 28756997
Cochrane Database Syst Rev. 2020 Feb 28;2:CD001168
pubmed: 32108333
Expert Opin Emerg Drugs. 2010 Dec;15(4):713-26
pubmed: 21091397
Br J Dermatol. 2003 Nov;149(5):960-7
pubmed: 14632799
Oral Dis. 2017 Jul;23(5):660-668
pubmed: 28168769
J Biomed Biotechnol. 2012;2012:759626
pubmed: 22675259
Oral Oncol. 2017 May;68:92-102
pubmed: 28438300
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009 Jun;107(6):796-800
pubmed: 19464654
Oral Dis. 2018 Jul;24(5):772-777
pubmed: 29297958
Cochrane Database Syst Rev. 2011 Jul 06;(7):CD001168
pubmed: 21735381
J Cutan Med Surg. 2012 Jul-Aug;16(4):221-9
pubmed: 22784514
Oral Surg Oral Med Oral Pathol Oral Radiol. 2016 Jul;122(1):72-80
pubmed: 27260276
Int J Dermatol. 2015 Sep;54(9):996-1004
pubmed: 26204904
N Engl J Med. 2012 Feb 23;366(8):723-32
pubmed: 22356325
J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1107-13
pubmed: 25308924
Br J Dermatol. 2019 Dec;181(6):1166-1176
pubmed: 30903622
Chin Med Sci J. 2015 Dec;30(4):210-7
pubmed: 26960301
Int J Clin Exp Med. 2013 Oct 25;6(10):917-21
pubmed: 24260597
J Eur Acad Dermatol Venereol. 2017 Feb;31(2):e85-e86
pubmed: 27291784
J Oral Pathol Med. 2022 Jan;51(1):63-73
pubmed: 34133803
J Am Acad Dermatol. 2002 Jan;46(1):35-41
pubmed: 11756943
J Cutan Med Surg. 2015 Nov-Dec;19(6):539-45
pubmed: 26088501
Periodontol 2000. 2019 Jun;80(1):105-125
pubmed: 31090143
J Am Dent Assoc. 2014 Jan;145(1):45-56
pubmed: 24379329
Biomed Pharmacother. 2021 Jul;139:111545
pubmed: 33873145
Oral Dis. 2019 Apr;25(3):693-709
pubmed: 29738106
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010 Jul;110(1):e19-25
pubmed: 20610291
Int J Dermatol. 2016 Jan;55(1):101-5
pubmed: 26147635
J Investig Clin Dent. 2017 Nov;8(4):
pubmed: 27633647
Int J Dermatol. 2012 Nov;51(11):1371-8
pubmed: 23067089
Oral Maxillofac Surg Clin North Am. 2013 Feb;25(1):93-100, vii
pubmed: 23399399
J Dermatolog Treat. 2021 May;32(3):367-371
pubmed: 31390902
J Dermatolog Treat. 2004 Sep;15(5):308-14
pubmed: 15370399
J Am Acad Dermatol. 2002 Jan;46(1):27-34
pubmed: 11756942
JAMA Dermatol. 2021 May 1;157(5):549-558
pubmed: 33787818
Eur J Dermatol. 2003 Sep-Oct;13(5):466-70
pubmed: 14693491
Oral Dis. 2017 Nov;23(8):1029-1042
pubmed: 28055124
Br J Dermatol. 2012 May;166(5):938-47
pubmed: 22242640
Oral Dis. 2021 May;27(4):813-828
pubmed: 32144836
Arch Dermatol. 2004 Dec;140(12):1508-12
pubmed: 15611431
Oral Dis. 2022 Apr;28(3):670-681
pubmed: 33529456